Hi Ravish
Nice presentation…What do u expect in the upcoming results
Dear Ravishji, your PPT is very useful in understanding the 3B Blackbio evolution, I am also invested in this company for last five months.
My investment thesis is very simple, molecular diagnostics segment of health care sector is growing at a CAGR of 20-25% in India. The segment is at a very nascent stage and is mainly dominated by foreign multi national brands. Most of the Mdx kits cost thousand of rupees and kits for some of the serious diseases are always in shortage. Very few indigenous companies are able to crack this market due to serious R&D required, difficulty in matching quality standards of foreign brands and difficulty in establishing distribution network with diagnostic labs and hospitals.
3B Black Bio , subsidiary of Kilpest India formed in 2011 managed to create and established a brand called TRUPCR in Indian market, company managed to generate profit in its 5th year of operation and since then its business is growing at a rate of 75% CAGR. Company is continuously developing more and more assays to penetrate Indian market, as per my industry checks TRUPCR kits are gaining momentum and establishing itself as a strong indigenous brand. 3Bs base is very small as it is at a very nascent stage, even after growing for 75% CAGR for last two years, quarterly sales are at just 2 crores. PAT margins are very high around 40%. This microcap can generate significant amount of wealth for shareholders if company is able to continue the hard work and expand its business in MDx segment.
4 Likes
what is the market size for TRUPCR product?
Blackbio.pdf (1.1 MB)
About Rs. 150-200 Crores and expected to grow 4-5 times within a year as per the corporate presentation…refer to slide 10
2 Likes
thanks for info… I saw the presentation, but I am not satisfied… that’s y I asked this question. Highest CAGR is 20% for Molecular Diagnostics (Chart on top right) but they are estimating the market to multiply 4 times within 1 year?
The 20% CAGR is for international average not for India. I can say this market will grow more than 100%. Just note that Thyrocare and Dr. Lal path have started to take Molecular Diagnostic Based tests and have recently started to invest in hardware. Even mentions it in it’s AR 2016-17 on page 58. So overall sector is growing and as per the AR of Kilpest, infrastructure for MBD tech is on development mode which is also a huge booster for the company and its products.
Following questions are posed to me by some intelligent guys:
- Is this the only company working in India?
- Are these kits proprietary?
- How this 95% stake of kilpest in this innovative subsidiary will impact on future prospects of the company how will they use Biotools(spain) technology in future?
- Can this business be done with few crores of money and why anyone else cant do this business?
- What is the pricing gap in MNC product and company’s product?
I did not have answer to these question and now i am looking for them. We together can find them and study further for multifold return.
1 Like
Hi Ravish,
Thankyou fr yr report. Any idea for how long is this growth sustainable and are MBD kits reusable or are they a one time buy.
Tks and regards
Investor presentation
Mdx business is getting better each quarter, results are very good, do not compare with Q2FY18 as Q2 will always be very strong due to sale of dengue and chikunguniya detection kits. I think they haven’t launched a new product this quarter but product pipeline remains very strong.
1 Like
Investor Presentation.
Kilpest stand alone performance isnt that good. BlackBio delivers another great set of results to give a so-so consolidated result.
1 Like
EPS is good, topline is good. They have given clarification that pesticide worth 72 lakhs would have been delivered in June quarter but due to government inspections it got delayed. Good results overall!
We have to be very patient for this stock, in my opinion valuation is very high with comparison to the current financials. It may take 2 to 3 years to clock revenue in high double digits. This sector is also a sun-rising sector in the world with many new diagnostic techniques on papers. How will this specific diagnostics wins the race will be a tedious task ahead for us as a investor here. One more concern i am looking at is the rate with New Labs or Customer are being added, Lets have a look
FY16-17 Q4- 12 NEW CUSTOMERS
FY17-18 Q1- 7 NEW CUSTOMERS
FY17-18 Q2- 8 NEW CUSTOMERS
FY17-18 Q3- 7 NEW CUSTOMERS
FY17-18 Q4- 6 NEW CUSTOMERS
FY180-19 Q1- 6 NEW CUSTOMERS
Lets us assume that it will add them in same manner so 24 new customers every year. This quarter they have mentioned for long term contract which will be a game changer for them.
3 Likes
3B Black Bio Biotech…exploring biz opportunities in African continent
If you go in detail about its products you might not look at its financials then. Everyone is looking at financials of the subsidiary company. I would suggest everyone to go through the products of the company. Visit 3b blackbio biotech Limited website and instead of talking about what it has - look at how it has.
one should go in details of the product and just look 2 things Product and raw material. Just looking at diagnostic kits and Raw material (where does it procure raw material or it is also a manufacturer of raw material) can unfold many answers.
5 Likes
Whatever points you have mentioned above will definitely help this forum and if you done above analysis then please share here so that every can get more info on it.
Thank u.
Nice article on performance of 3b kits
1 Like
Can anyone comment on the below news:
CARE has withdrawn the outstanding ratings of ‘CARE BB,Positive/CARE A4’ *Double B Minus;
Outlook:Positive/ A Four] assigned to the bank facilities of Kilpest India Limited with immediate effect. The above action has been taken at the
request of Kilpest India Limited and ‘No Objection Certificate’ received from the bank(s) that have extended the facilities rated by CARE.
Why should a company request to withdraw rating? to save the rating fee paid? So does it means the dont require loans in future? What exactly we will Inher from above? can any experience persons comment on the same.
[www.careratings.com/upload/CompanyFiles/PR/Kilpest India Limited-03-11-2019.pdf](http://www.careratings.com/upload/CompanyFiles/PR/Kilpest India Limited-03-11-2019.pdf)
1 Like
The possible reason could be that the company has become ‘Debt Free’ now. Hence, Credit Rating not required.
1 Like
I am talking about 3B black bio only. As promised top-line growth is not in three digits and as the commentary by the managements suggest same traction in future earning at least for next year will be good for company. Number of customers have jumped very fast from 100 in FY18 to 152 in FY19 as mentioned in investor presentation. My concern is increase in receivables which translate in to cash flow and controls various factors such as working capital , debt, missed investment opportunity and confidence of investors. Most of it is from Pesticide business but the increase of receivables at consolidated level is also alarming. I have read in one Valuepickr forum that it is more prudent to cut your margin and expand revenue exponentially and i am also of this opinion here also. I would also like to know how this dividend from subsidiary is taxed and distributed to shareholders. If it is only from subsidiary to company and still attracts 15% tax than is it not loss to us as a shareholder.
Please give some thought on it.
1 Like
I don’t think that the trade receivables are increasing alarmingly(as per the published results). The standalone trade receivables are ( FY16 - FY 19 )13.04, 13.2 , 14.16, 14.11 Crores. Where consolidated figures shows, again, (FY16 - FY 19 ) 13.43, 14.22, 16.48, 18.48 Crores . So assuming the trade receivables of the subsidiary gives approximately 0.41, 1.02, 2.32, 4.37 Crores, which is almost in line with the last one previous quarter of sales figure in subsidiary. Also along with the sales growth, I think it’s justifiable. Expert opinions please.